Stock Events

Stock Events

OmniAb 

$1.69
0
-$0.1-5.59% Monday 04:17

Statistics

Day High
1.69
Day Low
1.69
52W High
-
52W Low
-
Volume
3
Avg. Volume
-
Mkt Cap
243.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.14
-0.12
-0.11
-0.09
Expected EPS
-0.104286
Actual EPS
N/A

Financials

-235.05%Profit Margin
Unprofitable
2021
2022
2023
2024
52.78MRevenue
-124.07MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OABI.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is a leading biotech company that competes with OmniAb in the development of monoclonal antibodies for various therapeutic areas.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biopharmaceutical company that competes in the discovery, development, and manufacturing of human therapeutics, including monoclonal antibodies, similar to OmniAb's focus.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company is a competitor due to its strong focus on antibody therapies, including its efforts in immunology and oncology, areas that overlap with OmniAb's interests.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences competes with OmniAb in the biopharmaceutical field, particularly in the development of treatments that involve monoclonal antibodies for infectious diseases, among others.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in the discovery and development of innovative medicines, including monoclonal antibodies for cancer and other diseases, making it a competitor to OmniAb.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. competes with OmniAb through its extensive research and development in biopharmaceuticals, including therapies based on monoclonal antibodies for various diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that competes with OmniAb in the development and commercialization of biopharmaceuticals, including monoclonal antibodies for a wide range of conditions.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a competitor because of its focus on the development of biopharmaceuticals, including monoclonal antibodies for the treatment of diseases in areas like oncology, which overlaps with OmniAb's focus.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG competes with OmniAb through its subsidiary Genentech in the research and development of monoclonal antibody therapies, particularly in oncology and immunology.
Sanofi
SNY
Mkt Cap124.45B
Sanofi competes with OmniAb in the global healthcare market, particularly in the development of monoclonal antibodies for immunological diseases, an area of focus for OmniAb.

About

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Show more...
CEO
ISIN
US68218J1034

Listings

XNAS
US
OABI
XNAS
US
OABIW
BOATS
BOATS
OABI.BOATS

0 Comments

Share your thoughts

FAQ

What is OmniAb stock price today?▼
The current price of OABI.BOATS is $1.69 USD — it has decreased by -5.59% in the past 24 hours. Watch OmniAb stock price performance more closely on the chart.
What is OmniAb stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange OmniAb stocks are traded under the ticker OABI.BOATS.
What is OmniAb market cap?▼
Today OmniAb has the market capitalization of 243.28M
When is the next OmniAb earnings date?▼
OmniAb is going to release the next earnings report on May 07, 2026.
What were OmniAb earnings last quarter?▼
OABI.BOATS earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.09 USD resulting in a -25.04% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is OmniAb revenue for the last year?▼
OmniAb revenue for the last year amounts to 52.78M USD.
What is OmniAb net income for the last year?▼
OABI.BOATS net income for the last year is -124.07M USD.
When did OmniAb complete a stock split?▼
OmniAb has not had any recent stock splits.